MicroRNA networks in pulmonary arterial hypertension: Share mechanisms with cancer?

Current Opinion in Oncology

Volumn 28, Issue 1, 2016, Pages 72-82

  Courboulin, Audrey ^a   Ranchoux, Benoît ^b   Cohen Kaminsky, Sylvia ^a   Perros, Frédéric ^a,b   Bonnet, Sébastien ^b  

^a CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Cancers; microRNA; pulmonary hypertension

Indexed keywords

MICRORNA; MICRORNA 124; MICRORNA 126; MICRORNA 130; MICRORNA 138; MICRORNA 143; MICRORNA 145; MICRORNA 17; MICRORNA 204; MICRORNA 208; MICRORNA 21; MICRORNA 210; MICRORNA 223; MICRORNA 27A; MICRORNA 301; MICRORNA 424; MICRORNA 503; MICRORNA 92; MICRORNA 96; MICRORNA 98; UNCLASSIFIED DRUG;

BIOGENESIS; DISEASE COURSE; GENE FUNCTION; NEOPLASM; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; GENE REGULATORY NETWORK; GENETICS; HUMAN; METABOLISM; PATHOPHYSIOLOGY;

GENE REGULATORY NETWORKS; HUMANS; HYPERTENSION, PULMONARY; MICRORNAS; NEOPLASMS;

EID: 84951569500     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000253     Document Type: Review

References (129)

1. Tuder RM, Archer SL, Dorfmü ller P, et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol 2013; 62 (25 Suppl):D4-D12.
2. Humbert M, Montani D, Perros F, et al. Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension. Vascul Pharmacol 2008; 49:113-118.
3. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 2012; 122:4306-4313.
4. Ryan J, Dasgupta A, Huston J, et al. Mitochondrial dynamics in pulmonary arterial hypertension. J Mol Med Berl Ger 2015; 93:229-242.
5. Ranchoux B, Antigny F, Rucker-Martin C, et al. Endothelial-to-mesenchymal transition in pulmonary hypertension. Circulation 2015; 131:1006-1018.
6. Cohen-Kaminsky S, Hautefort A, Price L, et al. Inflammation in pulmonary hypertension: what we know and what we could logically and safely target first. Drug Discov Today 2014; 19:1251-1256.
7. Guignabert C, Tu L, Le Hiress M, et al. Pathogenesis of pulmonary arterial hypertension: lessons from cancer. Eur Respir RevV 22 2013; 543-551.
8. Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 2014; 15:509-524.
9. Li Z, Rana TM. Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discov 2014; 13:622-638.
10. Brock M, Trenkmann M, Gay RE, et al. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Circ Res 2009; 104:1184-1191.
11. Chen T, Zhou G, Zhou Q, et al. Loss of microRNA-17-92 in smooth muscle cells attenuates experimental pulmonary hypertension via induction of PDZ and LIM domain 5. Am J Respir Crit Care Med 2015; 191:678-692.
12. Caruso P, MacLean MR, Khanin R, et al. Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline. Arterioscler Thromb Vasc Biol 2010; 30:716-723.
13. Bockmeyer CL, Maegel L, Janciauskiene S, et al. Plexiform vasculopathy of severe pulmonary arterial hypertension and microRNA expression. J Heart Lung Transplant 2012; 31:764-772.
14. Zhu H, Han C, Lu D, Wu T. miR-17-92 cluster promotes cholangiocarcinoma growth: evidence for PTEN as downstream target and IL-6/Stat3 as upstream activator. Am J Pathol 2014; 184:2828-2839.
15. Hayashita Y, Osada H, Tatematsu Y, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005; 65:9628-9632.
16. Chow TF, Mankaruos M, Scorilas A, et al. The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma. J Urol 2010; 183:743-751.
17. Meng W-J, Yang L, Ma Q, et al. MicroRNA expression profile reveals miR-17-92 and miR-143-145 cluster in synchronous colorectal cancer. Medicine (Baltimore) 2015; 94:e1297.
18. Tsuchida A, Ohno S, Wu W, et al. miR-92 is a key oncogenic component of the miR-17-92 cluster in colon cancer. Cancer Sci 2011; 102:2264-2271.
19. O'Donnell KA, Wentzel EA, Zeller KI, et al. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005; 435:839-843.
20. Li Y, Choi PS, Casey SC, et al. MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic state. Cancer Cell 2014; 26:262-272.
21. Wang F, Li T, Zhang B, et al. MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun 2013; 434:688-694.
22. Drake KM, Zygmunt D, Mavrakis L, et al. Altered microRNA processing in heritable pulmonary arterial hypertension: an important role for Smad-8. Am J Respir Crit Care Med 2011; 184:1400-1408.
23. Parikh VN, Jin RC, Rabello S, et al. MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach. Circulation 2012; 125:1520-1532.
24. Sarkar J, Gou D, Turaka P, et al. MicroRNA-21 plays a role in hypoxiamediated pulmonary artery smooth muscle cell proliferation and migration. Am J Physiol Lung Cell Mol Physiol 2010; 299:L861-L871.
25. Green DE, Murphy TC, Kang B-Y, et al. PPARg ligands attenuate hypoxiainduced proliferation in human pulmonary artery smooth muscle cells through modulation of microRNA-21. PLoS ONE 2015; 10:e0133391.
26. Yang S, Banerjee S, Freitas ADE, et al. miR-21 regulates chronic hypoxiainduced pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol 2012; 302:L521-L529.
27. Lei M, Xie W, Sun E, et al. MicroRNA-21 regulates cell proliferation and migration and cross talk with PTEN and p53 in bladder cancer. DNA Cell Biol 2015; 34:629-632.
28. Bera A, Ghosh-Choudhury N, Dey N, et al. NFkB-mediated cyclin D1 expression by microRNA-21 influences renal cancer cell proliferation. Cell Signal 2013; 25:2575-2586.
29. Venturutti L, Romero LV, Urtreger AJ, et al. Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis. Oncogene 2015. [Epub ahead of print]
30. Huang W, Kang X-L, Cen S, et al. High-level expression of microRNA-21 in peripheral blood mononuclear cells is a diagnostic and prognostic marker in prostate cancer. Genet Test Mol Biomarkers 2015; 19:469-475.
31. Kang B-Y, Park KK, Green DE, et al. Hypoxia mediates mutual repression between microRNA-27a and PPARg in the pulmonary vasculature. PloS One 2013; 8:e79503.
32. Cacoub P, Dorent R, Nataf P, et al. Endothelin-1 in the lungs of patients with pulmonary hypertension. Cardiovasc Res 1997; 33:196-200.
33. Guttilla IK, White BA. Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem 2009; 284:23204-23216.
34. Goto T, Takano M, Albergaria A, et al. Mechanism and functional consequences of loss of FOXO1 expression in endometrioid endometrial cancer cells. Oncogene 2007; 27:9-19.
35. Dong X-Y, Chen C, Sun X, et al. FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer. Cancer Res 2006; 66:6998-7006.
36. Zhang B, Gui LS, Zhao XL, et al. FOXO1 is a tumor suppressor in cervical cancer. Genet Mol Res 2015; 14:6605-6616.
37. Tang W, Zhu J, Su S, et al. MiR-27 as a prognostic marker for breast cancer progression and patient survival. PloS One 2012; 7:e51702.
38. Tanaka K, Miyata H, Sugimura K, et al. miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts. Carcinogenesis 2015; 36:894-903.
39. Lee J-J, Drakaki A, Iliopoulos D, Struhl K. MiR-27b targets PPARg to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells. Oncogene 2012; 31:3818-3825.
40. Wallace E, Morrell NW, Yang XD, et al. A sex-specific microRNA-96/5-hydroxytryptamine 1B axis influences development of pulmonary hypertension. Am J Respir Crit Care Med 2015; 191:1432-1442.
41. Lin H, Dai T, Xiong H, et al. Unregulated miR-96 induces cell proliferation in human breast cancer by downregulating transcriptional factor FOXO3a. PloS One 2010; 5:e15797.
42. Schaefer A, Jung M, Mollenkopf H-J, et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 2010; 126:1166-1176.
43. Yu S, Lu Z, Liu C, et al. MiRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Cancer Res 2010; 70:6015-6025.
44. Zhang Q, Ren W, Huang B, et al. MicroRNA-183/182/96 cooperatively regulates the proliferation of colon cancer cells. Mol Med Rep 2015; 12:668-674.
45. Fendler A, Jung M, Stephan C, et al. The antiapoptotic function of miR-96 in prostate cancer by inhibition of FOXO1. PloS One 2013; 8:e80807.
46. Haflidadó ttir BS, Larne O, Martin M, et al. Upregulation of miR-96 enhances cellular proliferation of prostate cancer cells through FOXO1. PloS One 2013; 8:e72400.
47. Siu MK, Tsai Y-C, Chang Y-S, et al. Transforming growth factor-b promotes prostate bone metastasis through induction of microRNA-96 and activation of the mTOR pathway. Oncogene 2014; 34:4767-4776.
48. Kang B-Y, Park KK, Kleinhenz JM, et al. PPARg activation reduces hypoxiainduced endothelin-1 expression through upregulation of miR-98. Am J Respir Cell Mol Biol 2015.
49. Li F, Li X, Qiao L, et al. miR-98 suppresses melanoma metastasis through a negative feedback loop with its target gene IL-6. Exp Mol Med 2014; 46:e116.
50. Patel SAA, Gooderham NJ. IL6 mediates immune and colorectal cancer cell crosstalk via miR-21 and miR-29b. Mol Cancer ResMCR 2015. [Epub ahead of print]
51. Mayado A, Teodosio C, Garcia-Montero AC, et al. Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression. Leukemia 2015. [Epub ahead of print]
52. Lissat A, Joerschke M, Shinde DA, et al. IL6 secreted by Ewing sarcoma tumor microenvironment confers antiapoptotic and cell-disseminating paracrine responses in Ewing sarcoma cells. BMC Cancer 2015; 15:552.
53. Osuala KO, Sameni M, Shah S, et al. IL-6 signaling between ductal carcinoma in situ cells and carcinoma-associated fibroblasts mediates tumor cell growth and migration. BMC Cancer 2015; 15:584.
54. Paulin R, Meloche J, Bonnet S. STAT3 signaling in pulmonary arterial hypertension. JAKSTAT 2012; 1:223-233.
55. Humbert M, Monti G, Brenot F, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995; 151:1628-1631.
56. Soon E, Holmes AM, Treacy CM, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 2010; 122:920-927.
57. Steiner MK, Syrkina OL, Kolliputi N, et al. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 2009; 104:236-244.
58. Golembeski SM, West J, Tada Y, Fagan KA. Interleukin-6 causes mild pulmonary hypertension and augments hypoxia-induced pulmonary hypertension in mice. Chest 2005; 128 (6 Suppl):572S-573S.
59. Miyata M, Sakuma F, Yoshimura A, et al. Pulmonary hypertension in rats. 2. Role of interleukin-6. Int Arch Allergy Immunol 1995; 108:287-291.
60. Wang D, Zhang H, Li M, et al. MicroRNA-124 controls the proliferative, migratory, and inflammatory phenotype of pulmonary vascular fibroblasts. Circ Res 2014; 114:67-78.
61. Kang K, Peng X, Zhang X, et al. MicroRNA-124 suppresses the transactivation of nuclear factor of activated T cells by targeting multiple genes and inhibits the proliferation of pulmonary artery smooth muscle cells. J Biol Chem 2013; 288:25414-25427.
62. Bonnet S, Rochefort G, Sutendra G, et al. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci USA 2007; 104:11418-11423.
63. Itoh T, Nagaya N, Ishibashi-Ueda H, et al. Increased plasma monocyte chemoattractant protein-1 level in idiopathic pulmonary arterial hypertension. Respirol Carlton Vic 2006; 11:158-163.
64. Zhang M, Piao L, Datta J, et al. miR-124 regulates the epithelial-restricted with serine box/epidermal growth factor receptor signaling axis in head and neck squamous cell carcinoma. Mol Cancer Ther 2015; 10:2313-2320.
65. Cheng Y, Li Y, Nian Y, et al. STAT3 is involved in miR-124-mediated suppressive effects on esophageal cancer cells. BMC Cancer 2015; 15:306.
66. Liu S, Song L, Zeng S, Zhang L. MALAT1-miR-124-RBG2 axis is involved in growth and invasion of HR-HPV-positive cervical cancer cells. Tumour Biol 2015. [Epub ahead of print]
67. Xi Z-W, Xin S-Y, Zhou L-Q, et al. Downregulation of rho-associated protein kinase 1 by miR-124 in colorectal cancer. World J Gastroenterol 2015; 21:5454-5464.
68. Zheng Y-B, Xiao G-C, Tong S-L, et al. Paeoniflorin inhibits human gastric carcinoma cell proliferation through up-regulation of microRNA-124 and suppression of PI3K/Akt and STAT3 signaling. World J Gastroenterol 2015; 21:7197-7207.
69. Potus F, Malenfant S, Graydon C, et al. Impaired angiogenesis and peripheral muscle microcirculation loss contribute to exercise intolerance in pulmonary arterial hypertension. Am J Respir Crit Care Med 2014; 190:318-328.
70. Potus F, Ruffenach G, Dahou A, et al. Downregulation of miR-126 contributes to the failing right ventricle in pulmonary arterial hypertension. Circulation 2015; 132:932-943.
71. Nie Z-C, Weng W-H, Shang Y-S, et al. MicroRNA-126 is down-regulated in human esophageal squamous cell carcinoma and inhibits the proliferation and migration in EC109 cell via PI3K/AKT signaling pathway. Int J Clin Exp Pathol 2015; 8:4745-4754.
72. Xiong Y, Kotian S, Zeiger MA, et al. miR-126-3p inhibits thyroid cancer cell growth and metastasis, and is associated with aggressive thyroid cancer. PloS One 2015; 10:e0130496.
73. Wang C-Z, Yuan P, Li Y. miR-126 regulated breast cancer cell invasion by targeting ADAM9. Int J Clin Exp Pathol 2015; 8:6547-6553.
74. Miko E, Margitai Z, Czimmerer Z, et al. miR-126 inhibits proliferation of small cell lung cancer cells by targeting SLC7A5. FEBS Lett 2011; 585:1191-1196.
75. Luo P, Fei J, Zhou J, Zhang W. microRNA-126 suppresses PAK4 expression in ovarian cancer SKOV3 cells. Oncol Lett 2015; 9:2225-2229.
76. Wang J, Chen X, Su L, et al. MicroRNA-126 inhibits cell proliferation in gastric cancer by targeting LAT-1. Biomed Pharmacother 2015; 72:66-73.
77. Bertero T, Lu Y, Annis S, et al. Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension. J Clin Invest 2014; 124:3514-3528.
78. Pan Y, Wang R, Zhang F, et al. MicroRNA-130a inhibits cell proliferation, invasion and migration in human breast cancer by targeting the RAB5A. Int J Clin Exp Pathol 2015; 8:384-393.
79. Liu L, Nie J, Chen L, et al. The oncogenic role of microRNA-130a/301a/454 in human colorectal cancer via targeting Smad4 expression. PloS One 2013; 8:e55532.
80. Li S, Ran Y, Zhang D, et al. MicroRNA-138 plays a role in hypoxic pulmonary vascular remodelling by targeting Mst1. Biochem J 2013; 452:281-291.
81. Sen A, Ren S, Lerchenmü ller C, et al. MicroRNA-138 regulates hypoxiainduced endothelial cell dysfunction by targeting S100A1. PLoS One 2013; 8:e78684.
82. Yu C, WangM, Li Z, et al. MicroRNA-138-5p regulates pancreatic cancer cell growth through targeting FOXC1. Cell Oncol Dordr 2015; 38:173-181.
83. Yeh Y-M, Chuang C-M, Chao K-C, Wang L-H. MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1a. Int J Cancer J Int Cancer 2013; 133:867-878.
84. Wang Y, Zhang Z, Wang H, et al. miR-138-1-regulates aflatoxin B1-induced malignant transformation of BEAS-2B cells by targeting PDK1. Arch Toxicol 2015. [Epub ahead of print]
85. Qiu S, Huang D, Yin D, et al. Suppression of tumorigenicity by microRNA-138 through inhibition of EZH2-CDK4/6-pRb-E2F1 signal loop in glioblastoma multiforme. Biochim Biophys Acta 2013; 1832:1697-1707.
86. Rangrez AY, Massy ZA, Metzinger-Le Meuth V, Metzinger L. miR-143 and miR-145: molecular keys to switch the phenotype of vascular smooth muscle cells. Circ Cardiovasc Genet 2011; 4:197-205.
87. Caruso P, Dempsie Y, Stevens HC, et al. A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples. Circ Res 2012; 111:290-300.
88. Yoshino H, Enokida H, Itesako T, et al. Tumor-suppressive microRNA-143/145 cluster targets hexokinase-2 in renal cell carcinoma. Cancer Sci 2013; 104:1567-1574.
89. Zhang J, Sun Q, Zhang Z, et al. Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop. Oncogene 2013; 32:61-69.
90. Villadsen SB, Bramsen JB, Ostenfeld MS, et al. The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer. Br J Cancer 2012; 106:366-374.
91. Chen Y, Kelm RJ, Budd RC, et al. Inhibition of apoptosis and caspase-3 in vascular smooth muscle cells by plasminogen activator inhibitor type-1. J Cell Biochem 2004; 92:178-188.
92. Avgeris M, Mavridis K, Tokas T, et al. Uncovering the clinical utility of miR-143, miR-145 and miR-224 for predicting the survival of bladder cancer patients following treatment. Carcinogenesis 2015; 36:528-537.
93. Courboulin A, Paulin R, Giguè re NJ, et al. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med 2011; 208:535-548.
94. Wang X, Qiu W, Zhang G, et al. MicroRNA-204 targets JAK2 in breast cancer and induces cell apoptosis through the STAT3/BCl-2/survivin pathway. Int J Clin Exp Pathol 2015; 8:5017-5025.
95. Wu X, Zeng Y, Wu S, et al. MiR-204, down-regulated in retinoblastoma, regulates proliferation and invasion of human retinoblastoma cells by targeting CyclinD2 and MMP-9. FEBS Lett 2015; 589:645-650.
96. Shi Y, Huang J, Zhou J, et al. MicroRNA-204 inhibits proliferation, migration, invasion and epithelial-mesenchymal transition in osteosarcoma cells via targeting sirtuin 1. Oncol Rep 2015; 34:399-406.
97. Paffett ML, Lucas SN, Campen MJ. Resveratrol reverses monocrotalineinduced pulmonary vascular and cardiac dysfunction: a potential role for atrogin-1 in smooth muscle. Vascul Pharmacol 2012; 56:64-73.
98. Paulin R, Sutendra G, Gurtu V, et al. A miR-208-Mef2 axis drives the decompensation of right ventricular function in pulmonary hypertension. Circ Res 2015; 116:56-69.
99. Li H, Zheng D, Zhang B, et al. Mir-208 promotes cell proliferation by repressing SOX6 expression in human esophageal squamous cell carcinoma. J Transl Med 2014; 12:196.
100. Guo H, Xu Y, Fu Q. Curcumin inhibits growth of prostate carcinoma via miR-208-mediated CDKN1A activation. Tumour Biol 2015. [Epub ahead of print]
101. Yu P, Wu D, You Y, et al. miR-208-3p promotes hepatocellular carcinoma cell proliferation and invasion through regulating ARID2 expression. Exp Cell Res 2015; 336:232-241.
102. Liu A, Shao C, Jin G, et al. miR-208-induced epithelial to mesenchymal transition of pancreatic cancer cells promotes cell metastasis and invasion. Cell Biochem Biophys 2014; 69:341-346.
103. White K, Lu Y, Annis S, et al. Genetic and hypoxic alterations of the microRNA-210-ISCU1/2 axis promote iron-sulfur deficiency and pulmonary hypertension. EMBO Mol Med 2015; 7:695-713.
104. Tuder RM, Davis LA, Graham BB. Targeting energetic metabolism: a new frontier in the pathogenesis and treatment of pulmonary hypertension. Am J Respir Crit Care Med 2012; 185:260-266.
105. Gou D, Ramchandran R, Peng X, et al. miR-210 has an antiapoptotic effect in pulmonary artery smooth muscle cells during hypoxia. Am J Physiol Lung Cell Mol Physiol 2012; 303:L682-L691.
106. Jin Y, Pang T, Nelin LD, et al. MKP-1 is a target of miR-210 and mediate the negative regulation of miR-210 inhibitor on hypoxic hPASMC proliferation. Cell Biol Int 2015; 39:113-120.
107. Cui H, Seubert B, Stahl E, et al. Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes. Oncogene 2015; 34:3640-3650.
108. Zuo J, Wen M, Lei M, et al. MiR-210 links hypoxia with cell proliferation regulation in human laryngocarcinoma cancer. J Cell Biochem 2015; 116:1039-1049.
109. Wang J, Zhao J, Shi M, et al. Elevated expression of miR-210 predicts poor survival of cancer patients: a systematic review and meta-analysis. PloS One 2014; 9:e89223.
110. ZhanM, Li Y, Hu B, et al. Serum microRNA-210 as a predictive biomarker for treatment response and prognosis in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Vasc Interv Radiol 2014; 25:1279-1287.
111. Meloche J, Le Guen M, Potus F, et al. MiR-223 reverses experimental pulmonary arterial hypertension. Am J Physiol Cell Physiol 2015; 309: C363-C372.
112. Streppel MM, Pai S, Campbell NR, et al. MicroRNA 223 is upregulated in the multistep progression of Barrett's esophagus and modulates sensitivity to chemotherapy by targeting PARP1. Clin Cancer Res 2013; 19:4067-4078.
113. Hou B, Ishinaga H, Midorikawa K, et al. Circulating microRNAs as novel prognosis biomarkers for head and neck squamous cell carcinoma. Cancer Biol Ther 2015; 16:1042-1046.
114. Komatsu S, Ichikawa D, Miyamae M, et al. Malignant potential in pancreatic neoplasm; new insights provided by circulating miR-223 in plasma. Expert Opin Biol Ther 2015; 15:773-785.
115. Liang H, Yan X, Pan Y, et al. MicroRNA-223 delivered by platelet-derived microvesicles promotes lung cancer cell invasion via targeting tumor suppressor EPB41L3. Mol Cancer 2015; 14:58.
116. Wong QW-L, Lung RW-M, Law PT-Y, et al. MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology 2008; 135:257-269.
117. Kang W, Tong JHM, ChanAWH, et al. Stathmin1 plays oncogenic role and is a target of microRNA-223 in gastric cancer. PloS One 2012; 7:e33919.
118. Alli E, Yang J-M, Hait WN. Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. Oncogene 2007; 26:1003-1012.
119. Golouh R, Cufer T, Sadikov A, et al. The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study. Breast Cancer Res Treat 2008; 110:317-326.
120. Ghosh R, Gu G, Tillman E, et al. Increased expression and differential phosphorylation of stathmin may promote prostate cancer progression. Prostate 2007; 67:1038-1052.
121. Xi W, Rui W, Fang L, et al. Expression of stathmin/op18 as a significant prognostic factor for cervical carcinoma patients. J Cancer Res Clin Oncol 2009; 135:837-846.
122. Birnie KA, Yip YY, Ng DCH, et al. Loss of miR-223 and JNK signaling contribute to elevated stathmin in malignant pleural mesothelioma. Mol Cancer Res 2015; 13:1106-1118.
123. Kim J, Kang Y, Kojima Y, et al. An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension. Nat Med 2013; 19:74-82.
124. Schlosser K, Taha M, Deng Y, et al. Discordant regulation of microRNA between multiple experimental models and human pulmonary hypertension. Chest 2015; 148:481-490.
125. Oneyama C, Kito Y, Asai R, et al. MiR-424/503-mediated Rictor upregulation promotes tumor progression. PloS One 2013; 8:e80300.
126. Li B, Liu L, Li X, Wu L. miR-503 suppresses metastasis of hepatocellular carcinoma cell by targeting PRMT1. Biochem Biophys Res Commun 2015; 464:982-987.
127. Xiao F, Zhang W, Chen L, et al. MicroRNA-503 inhibits the G1/S transition by downregulating cyclin D3 and E2F3 in hepatocellular carcinoma. J Transl Med 2013; 11:195.
128. Chong Y, Zhang J, Guo X, et al. MicroRNA-503 acts as a tumor suppressor in osteosarcoma by targeting L1CAM. PloS One 2014; 9:e114585.
129. Long J,Ou C, Xia H, et al. MiR-503 inhibited cell proliferation of human breast cancer cells by suppressing CCND1 expression. Tumour Biol 2015. [Epub ahead of print]